

POLARSTEM[◊]/R3[◊] best performing cementless hip combination in the UK at 10 years¹

According to the 10-year results in the 18th Annual Report (2021) of the National Joint Registry for England, Wales, Northern Ireland, the Isle of Man and the States of Guernsey (based on cumulative percentage probability of revision)

Smith+Nephew

ODEP
10A*
POLARSTEM
Cementless Stem²

ODEP
10A*
R3
Cementless Cup²

65%
Lower revision risk with POLARSTEM/R3 compared to class average for cementless hip combinations at 10 years¹

10 years
98.23%
Highest survivorship of any cementless hip combination¹

Stem / cup brand	n	Median (IQR) age at primary	Percentage (%) males	Cumulative percentage probability of revision (95% CI) at:					
				1 year	3 years	5 years	10 years	15 years	17 years
Uncemented	465,982	-	-	0.96 (0.93-0.99)	1.75 (1.71-1.79)	2.54 (2.49-2.59)	5.06 (4.97-5.15)	7.89 (7.70-8.09)	8.81 (8.48-9.16)
Accolade™/ Trident™	27,158	66 (59 to 73)	44	0.94 (0.83-1.06)	1.89 (1.73-2.06)	2.53 (2.34-2.72)	4.10 (3.83-4.39)	<i>5.68 (4.97-6.47)</i>	<i>5.68 (4.97-6.47)</i>
Corail™ / Duraloc™ Cementless Cup	4,001	70 (64 to 75)	39	0.75 (0.53-1.08)	1.68 (1.32-2.13)	2.47 (2.02-3.01)	5.45 (4.74-6.25)	11.02 (9.74-12.46)	<i>12.89 (10.96-15.13)</i>
Corail / Trilogy™	3,281	67 (61 to 74)	40	0.59 (0.37-0.92)	1.09 (0.79-1.52)	1.64 (1.24-2.16)	2.94 (2.34-3.68)	<i>3.71 (2.79-4.91)</i>	<i>4.65 (3.25-6.65)</i>
Furlong HAC™ Stem / CSF™	17,104	69 (63 to 76)	40	1.11 (0.96-1.28)	1.83 (1.64-2.05)	2.23 (2.01-2.46)	3.60 (3.31-3.92)	5.17 (4.73-5.64)	5.79 (5.17-6.49)
Corail / ASR™ Resurfacing Cup	2,747	61 (54 to 67)	54	0.98 (0.68-1.43)	7.43 (6.50-8.48)	23.56 (22.00-25.22)	43.87 (41.97-45.82)	<i>48.52 (46.42-50.66)</i>	-
Corail / Pinnacle™	170,277	66 (59 to 73)	45	0.77 (0.73-0.81)	1.47 (1.41-1.53)	2.14 (2.07-2.22)	4.55 (4.41-4.70)	7.39 (7.00-7.81)	-
SL-PLUS [◊] Cementless Stem / EP-FIT [◊] PLUS	3,797	66 (59 to 74)	43	1.46 (1.12-1.89)	3.13 (2.62-3.74)	4.49 (3.87-5.22)	7.34 (6.47-8.32)	<i>9.07 (7.91-10.39)</i>	-
ANTHOLOGY [◊] / R3 Cementless	4,924	62 (53 to 69)	42	1.11 (0.85-1.45)	1.74 (1.41-2.16)	2.18 (1.78-2.66)	<i>3.68 (2.75-4.92)</i>	-	-
Corail / Pinnacle Gription™	10,711	66 (58 to 74)	41	0.93 (0.76-1.13)	1.55 (1.32-1.83)	2.21 (1.87-2.61)	<i>2.85 (2.36-3.45)</i>	-	-
Furlong HAC Stem / Furlong HAC CSF Plus	24,545	66 (59 to 73)	45	1.10 (0.98-1.24)	1.75 (1.59-1.92)	2.03 (1.86-2.22)	2.68 (2.45-2.93)	-	-
M/L Taper™ Cementless / Continuum™	6,203	61 (53 to 68)	50	1.23 (0.99-1.54)	1.78 (1.47-2.14)	2.15 (1.80-2.56)	<i>2.64 (2.21-3.15)</i>	-	-
Metafix™ Stem / Trinity™	6,949	64 (56 to 70)	46	0.77 (0.59-1.01)	1.11 (0.88-1.40)	1.39 (1.10-1.74)	<i>2.21 (1.60-3.06)</i>	-	-
POLARSTEM Cementless / R3 Cementless	19,140	66 (58 to 72)	46	0.75 (0.63-0.88)	1.00 (0.86-1.17)	1.20 (1.03-1.40)	<i>1.77 (1.42-2.20)</i>	-	-
SYNERGY [◊] Cementless Stem / R3 Cementless	3,871	65 (57 to 71)	52	0.88 (0.63-1.24)	1.29 (0.98-1.71)	1.71 (1.33-2.20)	3.26 (2.35-4.52)	-	-
Taperloc™ Cementless Stem / Exceed ABT™	26,557	65 (58 to 72)	44	1.10 (0.98-1.23)	1.50 (1.36-1.66)	1.76 (1.61-1.94)	2.32 (2.11-2.55)	-	-
Accolade II™/ Trident™	13,042	65 (57 to 72)	46	0.85 (0.70-1.03)	1.38 (1.17-1.64)	1.81 (1.45-2.27)	-	-	-
Furlong Evolution™ Cementless / Furlong HAC CSF Plus	5,133	62 (52 to 70)	39	1.33 (1.04-1.69)	1.83 (1.48-2.25)	2.13 (1.74-2.60)	-	-	-
M/L Taper Cementless / Trilogy IT	5,443	64 (55 to 71)	51	1.26 (1.00-1.60)	2.05 (1.69-2.48)	2.32 (1.93-2.80)	-	-	-
Taperloc™ Complete Cementless Stem / Exceed ABT™	3,737	63 (56 to 70)	49	0.86 (0.61-1.21)	1.34 (1.01-1.78)	1.60 (1.23-2.10)	-	-	-

Blue italics indicate that fewer than 250 cases remained at risk at these time points.

1. National Joint Registry for England, Wales and Northern Ireland: 18th Annual Report. Available at: <http://www.njrcentre.org.uk/njrcentre>. Accessed 21 September 2021. 2. Orthopaedic Data Evaluation Panel (ODEP). Available at <http://www.odep.org.uk>. Accessed 21 September 2021.

Acknowledgments: We thank the patients and staff of all the hospitals in England, Wales and Northern Ireland who have contributed data to the National Joint Registry. We are grateful to the Healthcare Quality Improvement Partnership (HQIP), the NJR Steering Committee and staff at the NJR Centre for facilitating this work. The views expressed represent those of the authors and do not necessarily reflect those of the National Joint Registry Steering Committee or the Health Quality Improvement Partnership (HQIP) who do not vouch for how the information is presented.